Abstract | PURPOSE: METHODS: RESULTS: After confirming the reproducibility of CT-based staging, we analyzed the survival of the patients. The multivariate analysis showed that the absence of arterial invasion on CT, the absence of lymph node swelling, and neoadjuvant therapy were independent prognostic factors. The three-year recurrence-free survival (RFS) rates in patients treated with and without neoadjuvant therapy were 78% and 58%, respectively (P = 0.0263). The adjusted overall survival (OS) (determined by the inverse probability of treatment weighting method using the inverse propensity score) was improved by neoadjuvant therapy (P = 0.00187); the hazard ratio was 0.3505. CONCLUSIONS: REGISTRATION: UMIN-CTR UMIN000015450.
|
Authors | S Kobayashi, A Tomokuni, K Gotoh, H Takahashi, H Akita, S Marubashi, T Yamada, T Teshima, K Fukui, Y Fujiwara, M Sakon |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 43
Issue 4
Pg. 763-771
(Apr 2017)
ISSN: 1532-2157 [Electronic] England |
PMID | 28100416
(Publication Type: Journal Article)
|
Copyright | Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved. |
Chemical References |
- Antimetabolites, Antineoplastic
- Deoxycytidine
- Gemcitabine
|
Topics |
- Aged
- Antimetabolites, Antineoplastic
(therapeutic use)
- Bile Duct Neoplasms
(diagnostic imaging, pathology, therapy)
- Biliary Tract Neoplasms
(diagnostic imaging, pathology, therapy)
- Chemoradiotherapy
- Cholangiocarcinoma
(diagnostic imaging, pathology, therapy)
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Female
- Gallbladder Neoplasms
(diagnostic imaging, pathology, therapy)
- Hepatectomy
- Humans
- Klatskin Tumor
(diagnostic imaging, pathology, therapy)
- Male
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Pancreaticoduodenectomy
- Retrospective Studies
- Survival Rate
- Tomography, X-Ray Computed
- Gemcitabine
|